Your browser is no longer supported. Please, upgrade your browser.
MITO Stealth BioTherapeutics Corp monthly Stock Chart
Stealth BioTherapeutics Corp
Index- P/E- EPS (ttm)-1.26 Insider Own- Shs Outstand36.39M Perf Week2.05%
Market Cap88.91M Forward P/E- EPS next Y-0.06 Insider Trans- Shs Float14.69M Perf Month-10.14%
Income-44.10M PEG- EPS next Q-0.03 Inst Own11.50% Short Float0.03% Perf Quarter19.02%
Sales21.10M P/S4.21 EPS this Y25.80% Inst Trans- Short Ratio0.04 Perf Half Y-39.02%
Book/sh0.07 P/B26.57 EPS next Y45.50% ROA-98.10% Target Price- Perf Year-84.65%
Cash/sh0.65 P/C2.85 EPS next 5Y- ROE-413.30% 52W Range0.90 - 14.41 Perf YTD-42.94%
Dividend- P/FCF- EPS past 5Y- ROI-205.50% 52W High-87.09% Beta-
Dividend %- Quick Ratio1.10 Sales past 5Y- Gross Margin- 52W Low106.62% ATR0.14
Employees73 Current Ratio1.10 Sales Q/Q- Oper. Margin- RSI (14)44.72 Volatility4.24% 7.41%
OptionableNo Debt/Eq6.08 EPS Q/Q65.90% Profit Margin- Rel Volume0.22 Prev Close1.81
ShortableYes LT Debt/Eq0.00 EarningsMay 07 BMO Payout- Avg Volume119.52K Price1.86
Recom2.40 SMA20-2.70% SMA50-3.63% SMA200-52.54% Volume25,740 Change2.77%
Apr-14-20Initiated ROTH Capital Buy $9
Apr-02-20Upgrade H.C. Wainwright Neutral → Buy $5
Dec-23-19Downgrade H.C. Wainwright Buy → Neutral $21 → $5
Dec-20-19Downgrade Evercore ISI Outperform → In-line
Mar-12-19Initiated Nomura Buy $23
Mar-12-19Initiated Jefferies Hold $16
Mar-12-19Initiated Evercore ISI Outperform $35
Jun-17-20 08:30AM  
Jun-04-20 06:40PM  
May-26-20 04:30PM  
May-14-20 09:41AM  
May-13-20 08:30AM  
May-08-20 06:30PM  
May-07-20 07:30AM  
May-04-20 06:00PM  
Apr-22-20 10:57AM  
Apr-13-20 08:25AM  
Apr-07-20 01:26PM  
Apr-01-20 07:30AM  
Mar-30-20 08:30AM  
Mar-03-20 07:30AM  
Feb-27-20 06:00PM  
Feb-18-20 07:00AM  
Jan-21-20 07:30AM  
Jan-09-20 06:20AM  
Jan-02-20 09:49AM  
Dec-26-19 07:55AM  
Dec-20-19 01:41PM  
Nov-19-19 04:30PM  
Nov-14-19 09:58AM  
Nov-11-19 08:00AM  
Oct-23-19 11:26AM  
Oct-17-19 07:30AM  
Oct-11-19 10:33AM  
Oct-10-19 07:30AM  
Oct-07-19 08:00AM  
Oct-01-19 08:00AM  
Sep-20-19 08:00AM  
Sep-17-19 09:22AM  
Sep-13-19 09:29AM  
Sep-03-19 04:30PM  
Aug-14-19 04:20PM  
Jul-02-19 08:00AM  
Jun-18-19 09:25AM  
May-30-19 08:00AM  
May-15-19 04:05PM  
May-14-19 04:15PM  
May-08-19 02:23PM  
Apr-30-19 04:23PM  
Apr-25-19 04:15PM  
Apr-16-19 06:01PM  
Apr-04-19 07:35PM  
Apr-02-19 08:00AM  
Mar-28-19 08:06AM  
Mar-12-19 03:30PM  
Mar-04-19 04:12PM  
Feb-10-19 06:51PM  
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases. The company's product candidates include SBT-20, a small peptide that targets and binds reversibly to cardiolipin, stabilizing mitochondrial structure, and function under conditions of oxidative stress; and SBT-272, a lead discovery pipeline compound, evaluating for rare neurodegenerative diseases, such as amyotrophic lateral sclerosis. Stealth BioTherapeutics Corp was founded in 2006 and is based in George Town, the Cayman Islands.